Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

VENUS REMEDIES vs NEULAND LABS - Comparison Results

Rs 100 invested in...

Loading...
DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    VENUS REMEDIES NEULAND LABS VENUS REMEDIES/
NEULAND LABS
 
P/E (TTM) x 15.0 25.4 59.1% View Chart
P/BV x 0.9 8.1 11.7% View Chart
Dividend Yield % 0.0 0.2 -  

Financials

 VENUS REMEDIES   NEULAND LABS
EQUITY SHARE DATA
    VENUS REMEDIES
Mar-23
NEULAND LABS
Mar-23
VENUS REMEDIES/
NEULAND LABS
5-Yr Chart
Click to enlarge
High Rs3792,004 18.9%   
Low Rs145966 15.0%   
Sales per share (Unadj.) Rs415.5928.4 44.8%  
Earnings per share (Unadj.) Rs19.9127.4 15.6%  
Cash flow per share (Unadj.) Rs44.0168.6 26.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Avg Dividend yield %00.7 0.0%  
Book value per share (Unadj.) Rs344.3774.8 44.4%  
Shares outstanding (eoy) m13.3712.83 104.2%   
Bonus / Rights / Conversions 00-  
Price / Sales ratio x0.61.6 39.4%   
Avg P/E ratio x13.211.7 113.1%  
P/CF ratio (eoy) x5.98.8 67.5%  
Price / Book Value ratio x0.81.9 39.7%  
Dividend payout %07.8 0.0%   
Avg Mkt Cap Rs m3,50119,052 18.4%   
No. of employees `000NANA-   
Total wages/salary Rs m5702,018 28.3%   
Avg. sales/employee Rs Th00-  
Avg. wages/employee Rs Th00-  
Avg. net profit/employee Rs Th00-  
INCOME DATA
Net Sales Rs m5,55511,912 46.6%  
Other income Rs m10397 105.9%   
Total revenues Rs m5,65812,009 47.1%   
Gross profit Rs m6022,718 22.1%  
Depreciation Rs m323528 61.2%   
Interest Rs m3131 2.2%   
Profit before tax Rs m3792,157 17.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m114522 21.8%   
Profit after tax Rs m2661,635 16.2%  
Gross profit margin %10.822.8 47.5%  
Effective tax rate %30.024.2 123.8%   
Net profit margin %4.813.7 34.8%  
BALANCE SHEET DATA
Current assets Rs m3,2307,609 42.4%   
Current liabilities Rs m8264,390 18.8%   
Net working cap to sales %43.327.0 160.1%  
Current ratio x3.91.7 225.6%  
Inventory Days Days376 580.2%  
Debtors Days Days5041,109 45.4%  
Net fixed assets Rs m2,7818,189 34.0%   
Share capital Rs m134129 103.6%   
"Free" reserves Rs m4,4709,812 45.6%   
Net worth Rs m4,6039,941 46.3%   
Long term debt Rs m387742 52.1%   
Total assets Rs m6,01115,798 38.0%  
Interest coverage x130.017.5 742.5%   
Debt to equity ratio x0.10.1 112.5%  
Sales to assets ratio x0.90.8 122.6%   
Return on assets %4.511.2 40.0%  
Return on equity %5.816.4 35.1%  
Return on capital %7.721.4 35.8%  
Exports to sales %073.5 0.0%   
Imports to sales %015.1 0.0%   
Exports (fob) Rs mNA8,750 0.0%   
Imports (cif) Rs mNA1,804 0.0%   
Fx inflow Rs m08,750 0.0%   
Fx outflow Rs m01,804 0.0%   
Net fx Rs m06,946 0.0%   
CASH FLOW
From Operations Rs m3662,372 15.4%  
From Investments Rs m-508-615 82.7%  
From Financial Activity Rs m-6-1,358 0.4%  
Net Cashflow Rs m-220403 -54.7%  

Share Holding

Indian Promoters % 41.8 32.8 127.3%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 29.1 5.5%  
FIIs % 1.6 22.7 7.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 58.2 67.2 86.7%  
Shareholders   19,560 27,723 70.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare VENUS REMEDIES With:   DIVIS LABORATORIES    CIPLA    SUN PHARMA    DR. REDDYS LAB    ZYDUS LIFESCIENCES    


More on VENUS REMEDIES vs NEULAND LABS

No comparison is complete without understanding how the stock prices have performed over a period of time.

Here's a brief comparison:

VENUS REMEDIES vs NEULAND LABS Share Price Performance

Period VENUS REMEDIES NEULAND LABS S&P BSE HEALTHCARE
1-Day 7.05% -1.12% 1.18%
1-Month -4.10% -11.56% -0.75%
1-Year 103.11% 269.91% 61.82%
3-Year CAGR 4.62% 43.81% 18.16%
5-Year CAGR 58.05% 59.26% 19.79%

* Compound Annual Growth Rate

Here are more details on the VENUS REMEDIES share price and the NEULAND LABS share price.

Moving on to shareholding structures...

The promoters of VENUS REMEDIES hold a 41.8% stake in the company. In case of NEULAND LABS the stake stands at 32.8%.

To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of VENUS REMEDIES and the shareholding pattern of NEULAND LABS.

Finally, a word on dividends...

In the most recent financial year, VENUS REMEDIES paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of 0.0%.

NEULAND LABS paid Rs 10.0, and its dividend payout ratio stood at 7.8%.

You may visit here to review the dividend history of VENUS REMEDIES, and the dividend history of NEULAND LABS.

For a sector overview, read our pharmaceuticals sector report.



Today's Market

Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising Sensex Today Rallies 639 Points | Suzlon Energy Surges 5%, Grasim Industries 4% | 3 Reasons Why Indian Share Market is Rising(Closing)

After opening the day on positive note, Indian share markets gained the momentum as the session progressed and ended on firm footing.